Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment

David W Dodick¹, Peter J Goadsby²,³, Christian Lucas⁴, Rigmor Jensen⁵, Jennifer N Bardos⁶, James M Martinez⁶, Chunmei Zhou⁶, Sheena K Aurora⁶, Jyun Yan Yang⁶, Robert R Conley⁶,⁷ and Tina Oakes⁶

Abstract

Objective: To report efficacy and safety of galcanezumab in adults with chronic cluster headache.

Background: Galcanezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide and inhibits its biological activity.

Methods: This study comprised a prospective baseline period, a 12-week double-blind, placebo-controlled treatment period, and a 52-week open-label period. Up to six protocol-specified concomitant preventive medications were allowed if patients were on a stable dose for 2 months prior to the prospective baseline period. Patients were randomized 1:1 to monthly subcutaneous galcanezumab (300 mg) or placebo. The primary endpoint was overall mean change from baseline in weekly attack frequency with galcanezumab compared to placebo. Key secondary endpoints were ≥50% response rate and percentage of patients meeting sustained response. Results from the double-blind treatment period are reported.

Results: A total of 237 patients were randomized and treated (120 placebo; 117 galcanezumab). At baseline, the mean age was 45 years and 63% were using ≥1 preventive drug. The primary endpoint was not met; mean change in weekly attack frequency was –4.6 placebo versus –5.4 galcanezumab (p = 0.334). Key secondary endpoints also were not met. Injection site-related treatment-emergent adverse events were more common in the galcanezumab than the placebo group, with significantly more injection site erythema.

Conclusion: Treatment with galcanezumab 300 mg did not achieve its primary and key secondary endpoints. This study underscores the potential distinct biology of cCH as well as the significant unmet need for safe, effective, and well-tolerated preventive treatment. The safety profile of galcanezumab in cCH is consistent with that observed in trials of episodic CH and migraine.

Trial registration: NCT02438826; https://www.clinicaltrials.gov/ct2/show/NCT02438826.

Keywords
Galcanezumab, chronic cluster headache, LY2951742, CGRP, humanized monoclonal antibody

Date received: 13 September 2019; revised: 21 December 2019; accepted: 16 January 2020
**Introduction**

Cluster headache (CH) is a primary headache disorder characterized by attacks of intense unilateral headache, restlessness or agitation, and ipsilateral cranial autonomic symptoms (1,2). Attacks occur near daily to multiple times daily during cluster periods. The two subtypes, episodic CH (eCH) and chronic CH (cCH), are differentiated by the presence and duration of attack-free remission periods. Chronic cluster headache, affecting up to 20% of patients (3), is associated with cluster periods lasting 1 year or longer without remission or with remission periods lasting less than 3 months (4). The disease burden of cCH is substantial (5). Current guidelines for CH prevention (6,7) are based on a small body of evidence and few controlled trials. Additional evidence-based preventive treatments are needed.

Calcitonin gene-related peptide (CGRP) is implicated in the pathophysiology of CH and migraine (8). CGRP is highly expressed in anatomical locations activated during cluster headache and migraine, such as the trigeminal ganglion neurons and peripheral projections of the trigeminal nerve (9,10). Similar to migraine (11,12), CGRP levels were elevated during CH attacks in patients with eCH and normalized after spontaneous resolution or acute treatment with oxygen or subcutaneous sumatriptan (13,14). More recently, infusion of CGRP was shown to induce cluster headache attacks in patients with episodic and less predictably in chronic CH (15).

Galcanezumab is a humanized monoclonal antibody that binds CGRP and prevents its biological activity (16). In Phase 3 trials in patients with episodic and chronic migraine, galcanezumab treatment demonstrated clinically meaningful changes in migraine headache days, and a favorable safety profile (17–19). Galcanezumab also demonstrated efficacy in reducing CH attack frequency in a Phase 3, randomized, double-blind, placebo-controlled study in patients with eCH (20). Here we report results from the 12-week double-blind period of a Phase 3 trial of galcanezumab in patients with eCH that have been reported in abstract form previously (21,22).

**Methods**

**Study design**

This Phase 3, multi-center, randomized, double-blind, placebo-controlled study of galcanezumab 300 mg for the prevention of eCH comprised periods (Figure 1): a) Screening/washout (0–65 days); b) prospective baseline (14–17 days); c) double-blind, placebo-controlled treatment (12 weeks); d) optional open-label extension (52 weeks); and e) post-treatment follow-up (washout) (16 weeks).

The prospective baseline period began after the patient completed screening and washout of excluded medications, and upon experiencing a CH attack (hereafter “attack”) and beginning to record their attack information and acute medication use in an electronic patient reported outcome (ePRO) diary. Fourteen consecutive days from the ePRO diary were used to determine eligibility, establish baseline attack frequency and baseline use of acute medications; hereafter, this 14-day eligibility period is referred to as the baseline period. Patients meeting entry criteria were then randomized (1:1) to 12 weeks of double-blind treatment with monthly subcutaneous injections of placebo or galcanezumab 300 mg. Treatment was assigned using a computer-generated random sequence generated by an interactive web response system, programmed using the dynamic allocation method (23) to balance treatment arms for gender, average daily attack frequency (≤ 4 attacks per day/ > 4 attacks per day), verapamil use (yes/no), and investigative site.

Investigational product was administered by blinded trained staff. Galcanezumab was supplied as a lyophilized formulation in glass vials, and placebo was administered as 0.9% sodium chloride for injection. Galcanezumab and placebo were administered by blinded personnel using single dose, disposable syringes that were visibly indistinguishable from each other, with blinded labels containing subject number and study name. Patients in both groups received three injections at each dosing visit. Syringe preparation was completed by designated unblinded site personnel, not involved in clinical aspects of the study, including investigational product administration, clinical evaluations, and adverse event assessments.

**Inclusion and exclusion criteria**

This study enrolled males and females, aged 18 to 65 years with a history of eCH, without a remission period, or with remissions lasting <1 month, for at least 1 year as defined by ICHD-3 beta (24), the criteria that were in effect until enrollment was completed. The diagnostic criteria for eCH have since been updated and the duration of the remission periods changed to <3 months (4). During the baseline period, patients must have had at least eight total attacks, at least one attack every other day, and a maximum of eight attacks/day (24).

Patients were excluded from the study if they had any current or past exposure to any CGRP antibody, any antibody to the CGRP receptor, or nerve growth factor antibodies. Patients suspected of having another distinct trigeminal autonomic cephalalgia (TAC) or using
indomethacin to treat another suspected TAC were also excluded. If indomethacin was used to treat another condition, patients had to complete a washout period prior to the prospective baseline period. Additionally, patients who had used botulinum toxin type A or type B in the head or neck area within 4 months of the prospective baseline period were declared a screen fail and discontinued; however, these patients were allowed to rescreen for the study once, after they had completed the 4-month washout period for botulinum toxin type A or type B. Patients with a serious or unstable medical condition that precluded study participation, including (but not limited to) patients with a significant risk for suicide, history of substance abuse or dependence in the past year, history of stroke or intracranial aneurysm, or at risk for serious or acute cardiovascular events based on history or electrocardiogram findings, were also excluded. Supplemental material 1 shows the complete details of all inclusion and exclusion criteria.

The following acute treatments for attacks were allowed: High-flow oxygen, oral triptans, subcutaneous and intranasal sumatriptan, intranasal zolmitriptan, acetaminophen/paracetamol, and non-steroidal anti-inflammatory drugs. Patients could use up to six prespecified preventive treatments for cCH (verapamil ≤ 480 mg/day, lithium, valproate, gabapentin, melatonin, and topiramate) provided they were on a stable dose for at least 2 months prior to the prospective baseline period and the dose remained stable throughout double-blind treatment. No other acute or preventive treatments for cCH were allowed.

Efficacy assessments

Patients recorded attack-related information in an ePRO diary daily during the prospective baseline period, double-blind treatment period, and the first month of the open-label period. Patients recorded the number of attacks, average attack duration, average attack pain severity, and acute medication use for cCH. Pain severity was rated as: 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe (25). The daily diary data were converted into biweekly intervals for analysis (weeks 1/2, 3/4, 5/6, 7/8, 9/10, and 11/12 for the double-blind period).

The primary endpoint was the overall mean change from baseline in weekly attack frequency across weeks 1–12 of the double-blind treatment period with galcanezumab compared with placebo. Key secondary endpoints were a) estimated mean percentage of patients with a ≥50% reduction from baseline in weekly attack frequency across weeks 1–12 and b) percentage of
patients meeting sustained response through week 12. Sustained response was defined as a ≥50% reduction in the weekly attack frequency from baseline to weeks 3/4 and maintained at weeks 5/6, weeks 7/8, weeks 9/10, and weeks 11/12. Patients discontinuing study treatment prior to weeks 11/12 were not considered sustained responders.

Other secondary assessments were: Mean change in weekly attack frequency from baseline to each 2-week interval through week 12; percentage of patients with a ≥50% reduction in weekly attack frequency from baseline at each 2-week interval through week 12; percentage of patients with a ≥30% reduction in weekly attack frequency from baseline at each 2-week interval through week 12; and percentage of patients reporting a score of 1 (“very much better”) or 2 (“much better”) on the Patient Global Impression of Improvement (PGI-I) scale at week 4, week 8, and week 12.

Pre-specified subgroup analyses for the primary efficacy measure included these variables: Sex, race, ethnicity, age, baseline average number of attacks, baseline verapamil use, and region. Overall baseline preventive use was a post-hoc subgroup analysis.

Clinical safety assessments

Treatment-emergent adverse events were defined as adverse events (AEs) first occurring or worsening during the double-blind period compared with baseline. Treatment-emergent AEs, serious AEs (SAEs), AEs leading to discontinuation, vital signs and weight, electrocardiograms, and laboratory measurements are reported. Suicidal ideation and behavior were assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS) (26).

Anti-drug antibody (ADA) status was determined using a proprietary validated assay that was based on an affinity capture elution ELISA, with an additional up-front acid pretreatment step (27,28). The assay was validated according to Food and Drug Administration guidance (29,30). This included validation of a minimal required dilution of 1:10 with a sensitivity of 2.9 ng/mL and a drug tolerance of galcanezumab 298.9 μg/mL at 125 ng/mL of surrogate material. Among patients evaluated for treatment-emergent-ADA, treatment emergent-ADA-positive was defined as having a baseline status of ADA not present and at least one post-baseline status of ADA-present with a titer ≥1:20 or having a baseline and post-baseline status of ADA-present, with the post-baseline titer being fourfold greater than the baseline titer.

Statistical analyses

Efficacy and safety analyses were conducted on intent-to-treat patients who were randomized and received at least one dose of investigational product. The primary endpoint of change from baseline in weekly attack frequency across weeks 1–12 was analyzed using a mixed-effects model repeated measures analysis with longitudinal observations at weeks 1/2, 3/4, 5/6, 7/8, 9/10, and 11/12. The model included fixed, categorical effects of treatment, sex, verapamil use, pooled investigative site, week, and treatment-by-week interaction, as well as the continuous, fixed covariate of baseline value. Sensitivity analyses were performed for the primary endpoint.

For the key secondary outcome of the estimated mean percentage of patients with a ≥50% reduction from baseline in the weekly attack frequency during the double-blind treatment period, a categorical, pseudo-likelihood-based repeated measures analysis was used. This analysis included fixed, categorical effects of treatment, sex, verapamil use, week, and treatment-by-week interaction, as well as the continuous, fixed covariate of baseline value.

For the key secondary outcome of sustained response, treatment differences in the percentage of patients meeting the sustained response definition were determined using Koch’s nonparametric randomization-based analysis of covariance method (31), which adjusted for continuous baseline value, sex, and verapamil use.

To maintain the overall type I error rate at a two-sided alpha level of 0.05 for the primary and key secondary endpoints, the Cui-Hung-Wang test statistic (32) was calculated for each due to sample size re-estimation at the interim analysis. A gate-keeping strategy was employed whereby significance of the treatment comparison for primary and key secondary endpoints was tested in a pre-specified order.

For other secondary efficacy outcomes and safety, treatment effects were evaluated based on a two-sided significance level of 0.05 without adjustment for multiplicity. A categorical, pseudo-likelihood-based repeated measures analysis was used to analyze the categorical longitudinal secondary efficacy outcomes, including at least 50% and at least 30% reduction in weekly attack frequency from baseline at each 2-week interval through week 12, and PGI-I at weeks 4, 8, and 12. Categorical comparisons between treatment groups for safety measures were performed using Fisher’s exact tests, where appropriate.

For the primary and secondary efficacy endpoints, for which data were captured with electronic diary use, if there were 8 or more days with non-missing diary data and the adherence to using the diary was more than 50% in the biweekly interval, the average number of cluster headache attacks across the non-missing days was used to impute the missing days. Otherwise, data for the biweekly interval were considered to be missing and were not imputed in the analyses.
Sample size. The protocol included a sample size re-estimation approach. Study sites were blinded to the details. The planned enrollment was a minimum of 162 participants with the opportunity to increase to a maximum of 222 at the first interim analysis based on a pre-defined sample size re-estimation, which provided power ranging between 73% and 89% for assumed effect sizes between 0.40 and 0.50 to detect a significant difference between placebo and galcanezumab 300 mg at a one-sided $\alpha = 0.025$. The power analysis was performed using EAST software version 6.2 assuming a 10% discontinuation rate.

Interim analyses. Two planned interim analyses were conducted. Safety analysis, futility analysis, and sample size re-estimation were conducted at the first interim analysis. For the first interim analysis, an independent data monitoring committee conducted an unblinded review of efficacy and safety data. The review included 106 randomized patients who received at least one dose, who had baseline and at least one post-baseline value of weekly attack frequency, and who completed the week 4 visit for sample size re-estimation and futility evaluation. The review also included 110 randomized patients with at least one dose for safety evaluation. Based on pre-specified criteria, the committee recommended a sample size increase to 222. No further study modifications were recommended.

The second interim analysis was performed on the final set of all randomized patients through the end of the double-blind period. The results from this second interim analysis are reported here.

Results

Patient disposition

This study was conducted at 39 study sites in 12 countries (Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Spain, United Kingdom, and United States). The first patient was enrolled on 29 July 2015; the last patient completed double-blind treatment on 27 March 2018.

Overall, 387 patients were screened and 147 patients did not meet screening criteria (Figure 2). Of 240 patients who were randomized to double-blind treatment, three patients in the placebo group did not receive treatment; thus, 237 patients (120 placebo; 117 galcanezumab) were included in the intent-to-treat population (Figure 2). Overall, 230 (97%) patients completed double-blind treatment. Three patients discontinued from placebo treatment (AE [n = 1]; lack of efficacy [n = 1]; subject withdrawal [n = 1]) and four patients discontinued from galcanezumab treatment (AE [n = 1]; protocol deviation [n = 2]; subject withdrawal [n = 1]). The two protocol deviations that led to discontinuation were having met a cardiovascular exclusion criterion (high Bazett’s QT interval prior to starting treatment) and taking an excluded medication (prednisone). The placebo- and galcanezumab-treated patients discontinued due to an AE of palpitations and an SAE of atrial fibrillation (lasting 1 day; patient diagnosed with thyroid nodules 3 weeks later), respectively (both resolved).

Baseline demographics

The patient population was predominately male (72.6%) and white (84.4%), with a mean age of 45.0 years (Table 1). Most patients were from Europe (82.7%). Overall, 63.3% of patients were taking at least one preventive medication and among these patients, 72%, 24%, 3%, and 1% were taking 1, 2, 3, and 4 preventatives, respectively. Approximately 50% of all patients were taking verapamil. Oxygen and subcutaneous sumatriptan were the most frequently used acute treatments (oxygen: 53.3% placebo; 65.0% galcanezumab; subcutaneous sumatriptan: 62.5% placebo; 63.3% galcanezumab). Most patients (83.1%) had ≤4 daily attacks during the baseline period (mean weekly attacks 18.8 ± 10.2; average pain severity 2.7 ± 0.7 [moderate-to-severe]). Before screening, 23.2% of patients reported lifetime suicidal ideation and 3.8% reported lifetime suicidal behavior.

Efficacy

The primary endpoint was not met. The mean reduction from baseline in weekly attack frequency across weeks 1–12 was −4.6 attacks with placebo versus −5.4 attacks with galcanezumab ($p = 0.334$) (Figure 3(a)). At weeks 1/2, there was a significantly greater mean change from baseline in weekly attack frequency with galcanezumab compared to placebo (−4.0 attacks vs −1.8 attacks, respectively; $p = 0.006$) (Figure 3(a); Table 2). No significant treatment group differences were observed at other biweekly intervals. Sensitivity analyses (data not shown) were performed and results were consistent with that of the primary efficacy analysis.

Key secondary endpoints were not met. The mean percentage of patients with a ≥50% reduction in weekly attack frequency from baseline across weeks 1 to 12 was 27.1% with placebo and 32.6% with galcanezumab ($p = 0.170$) (Figure 3(b); Table 2). A similar percentage of patients in each treatment group met the definition of sustained response (17.5% placebo; 16.2% galcanezumab; $p = 0.946$) (Figure 3(c)). Other secondary outcomes were also not met (Table 2).
Pre-specified subgroup analyses for the primary efficacy measure included sex, race, ethnicity, age, baseline average number of attacks, baseline verapamil use, and region. The treatment effect differed in North America versus Europe, with a greater overall mean reduction in weekly cluster headache attack frequency observed in Europe compared with North America (region-by-treatment interaction; $p = 0.007$). Subgroup-by-treatment interactions for sex, race, ethnicity, age, baseline average number of attacks, and baseline verapamil or preventive use were not statistically significant (Supplemental material 2; Table A). Post-hoc analyses were conducted to further understand the regional difference by searching for potential confounders or effect modifiers. An imbalance was observed in the following variables in North America: Baseline weekly attack frequency, baseline subcutaneous sumatriptan use, and lifetime suicidal ideation/behavior prior to screening (Supplemental material 2, Table B). There was also evidence of treatment-by-baseline subcutaneous sumatriptan use interaction (Supplemental material 2, Table C) with a greater reduction in attack frequency with galcanezumab compared to placebo in high-frequency users of subcutaneous sumatriptan (defined as > 7.031 times of baseline sumatriptan use per week) compared to the low-frequency users.

**Concomitant medication**

Acute medication including oxygen was used in 93.3% and 94.9% of patients in the placebo and galcanezumab groups, respectively, during the double-blind period. Subcutaneous sumatriptan (67.5% in each treatment group) and oxygen (53.3% placebo; 65.0% galcanezumab) were the most common. The percentages of patients using an allowed preventive medication were verapamil (53.3% placebo; 47.0% galcanezumab); lithium (15.0% placebo; 11.1% galcanezumab), topiramate (10.8% placebo; 7.7% galcanezumab), valproate (5.8% placebo; 6.8% galcanezumab), melatonin (1.7% placebo; 5.1% galcanezumab), and gabapentin (2.5% placebo; 2.6% galcanezumab). There were no significant differences between treatment groups for any acute or preventive medication.
The mean exposure duration during the double-blind period was 90.6 and 90.3 days for placebo and galcanezumab, respectively. Most patients (97.5%) received all three doses of study drug. Adverse events reported during the double-blind treatment period are summarized in Table 3. No deaths were reported. Three placebo-treated patients reported SAEs of melena, non-cardiac chest pain, and depression, all of which resolved. Two galcanezumab-treated patients each reported one SAE (atrial fibrillation [discontinued treatment] and constipation [no change to study treatment]) with both AEs noted as resolved. Constipation was judged by the investigator as treatment related.

A higher percentage of galcanezumab-treated patients reported treatment-emergent AEs (62.5% placebo; 71.8% galcanezumab), with the majority of patients (92.5%) reporting treatment-emergent AEs as mild or moderate. Injection site pain, nasopharyngitis, injection site erythema, and nausea were reported by ≥5% of galcanezumab-treated patients (Table 3), with injection site erythema reported by significantly more galcanezumab- than placebo-treated patients (0.8% placebo; 6.8% galcanezumab, \( p = 0.018 \)). During double-blind treatment, no patient reported suicidal behavior; similar numbers of placebo- (n = 6) and galcanezumab-treated (n = 5) patients reported suicidal ideation.

There were no clinically meaningful differences in laboratory parameters between treatment groups, and no patient met abnormal hepatic laboratory criteria (i.e. alanine aminotransferase or aspartate aminotransferase ≥3 × the upper limit of normal, alkaline phosphatase or total bilirubin ≥2 × the upper limit of normal). A statistically significant mean difference was observed for diastolic blood pressure (−1.7 mmHg placebo; 0.2 mmHg galcanezumab, least squares mean change difference: 1.9 mmHg; \( p = 0.044 \)) (Table 4); however, this was not associated with increases in reported hypertension AEs (2.5% placebo;
2.6% galcanezumab), or initiation of, or dose increases in antihypertensive medication (1.7% placebo; 1.7% galcanezumab). There were no statistically significant or clinically meaningful differences between placebo and galcanezumab in the percentage of patients with categorical increases in blood pressure, pulse, or weight or in quantitative or qualitative electrocardiograms.

Figure 3. Primary endpoint and key secondary endpoints. a) Least squares mean change from baseline in weekly cluster headache attack frequency. The primary endpoint is overall mean change from baseline in weekly cluster headache attack frequency across weeks 1–12. b) Mean percentage of patients achieving a response of ≥ 50% reduction in weekly cluster headache frequency across weeks 1–12 (first key secondary endpoint). c) Percentage of patients achieving a sustained response through week 12. A sustained response was defined as ≥ 50% reduction in the weekly cluster attack frequency from baseline to weeks 3/4 and maintained at weeks 5/6, 7/8, 9/10, and 11/12 (second key secondary endpoint). CHW adjusted p-values are shown.

BL: baseline; CHW: Cui, Hung, and Wang; GMB: galcanezumab; LS: least squares; N: population size; PBO: placebo; SE: standard error.
Table 2. Secondary efficacy outcomes.

|                                | Week 1/2 | Week 3/4 | Week 5/6 | Week 7/8 | Week 9/10 | Week 11/12 | Overall |
|--------------------------------|----------|----------|----------|----------|-----------|------------|---------|
| Change from baseline in weekly cluster headache attack frequency* |          |          |          |          |           |            |         |
| Placebo, least squares mean change from baseline (SE)             | −1.8 (0.7) | −3.8 (0.8) | −4.6 (0.9) | −5.2 (0.9) | −6.0 (1.0) | −6.2 (0.9) | −4.6 (0.8) |
| Galcanezumab 300 mg, least squares mean change from baseline (SE) | −4.0 (0.7)* | −4.2 (0.9) | −5.9 (0.9) | −6.1 (0.9) | −5.8 (1.0) | −6.3 (0.9) | −5.4 (0.8) |
| Estimated percentage of 50% responders for weekly cluster headache attack frequency* |          |          |          |          |           |            |         |
| Placebo, model estimated rate (SE), %                             | 13.3 (3.1) | 25.7 (4.2) | 29.4 (4.4) | 31.1 (4.5) | 30.2 (4.4) | 38.3 (4.7) | 27.1 (3.5) |
| Galcanezumab 300 mg, model estimated rate (SE)                     | 19.9 (3.8) | 27.1 (4.3) | 38.7 (4.8) | 34.6 (4.7) | 39.7 (4.9) | 38.6 (4.8) | 32.6 (3.8) |
| Estimated percentage of 30% responders for weekly cluster headache attack frequency* |          |          |          |          |           |            |         |
| Placebo, model estimated rate (SE)                                | 23.0 (3.9) | 39.1 (4.7) | 39.5 (4.7) | 42.9 (4.8) | 44.7 (4.8) | 47.2 (4.9) | 39.0 (3.9) |
| Galcanezumab 300 mg, model estimated rate (SE)                     | 35.2 (4.6)** | 45.5 (4.9) | 52.3 (5.0) | 53.8 (5.0) | 54.4 (5.0) | 53.7 (5.0) | 49.1 (4.1) |
| PGI-I* Percentage of patients with score 1 or 2 at each of weeks 4, 8, 12 |          |          |          |          |           |            |         |
| Placebo, model estimated rate (SE)                                | 19.4 (4.5) | 32.0 (5.5) | 35.6 (5.7) | 35.6 (5.7) | 28.4 (4.7) |            |         |
| Galcanezumab 300 mg, model estimated rate (SE)                     | 21.5 (4.8) | 32.1 (5.7) | 30.4 (5.5) | 30.4 (5.5) | 27.7 (4.7) |            |         |

*p = 0.006, CHW adjusted.

*p = 0.037.

*N=120 placebo and N=117 galcanezumab intent-to-treat patients with baseline and at least one post-baseline measurement.

*N=103 placebo and N=102 galcanezumab intent-to-treat patients with at least one post-baseline measurement.

CHW: Cui, Hung, and Wang; N: population size; PGI-I: Patient Global Impression of Improvement; SE: standard error.
Concomitant use of galcanezumab and verapamil did not lead to increases in treatment-emergent cardiovascular events, including bradycardia, first degree atrioventricular block, dizziness, or dyspnea events during double-blind treatment. There were no reports of treatment-emergent heart failure, congestive heart failure, pulmonary edema, rapid ventricular response, or second- or third-degree atrioventricular block.

There were 14 patients with ADA present at baseline, and one galcanezumab-treated patient with treatment-emergent ADA during the double-blind period, with no TEAEs reported.

**Discussion**

To our knowledge this is one of the largest completed randomized, placebo-controlled trials to investigate the efficacy and safety of a preventive treatment for cCH. Similar to the eCH study (20), this study in patients with cCH evaluated whether galcanezumab reduced the frequency of weekly attacks, an endpoint consistent with the 1995 IHS guideline (25). In this cCH study, the primary endpoint, reduction in attack frequency across weeks 1–12, and key secondary objectives were not met. This is in contrast to the eCH study, which demonstrated that galcanezumab significantly reduced the number of weekly CH attacks across weeks 1–3 (20). In the eCH study, the early primary endpoint (across weeks 1–3) was necessary to ensure an adequate test prior to spontaneous remission as noted in the IHS guideline (25); however, for cCH, a durable effect measured across weeks 1–12 was chosen due to the largely unremitting nature of the disorder. While not observed at any other biweekly interval, a significantly greater reduction in the weekly attack frequency was observed with galcanezumab compared to placebo at weeks 1/2.

With regard to the regional difference between Europe and North America on the primary endpoint, the results of the post hoc analyses provide evidence that the observed interaction by region could be partially induced by both imbalance of the confounders (baseline weekly attack frequency; baseline subcutaneous sumatriptan use; and lifetime suicidal ideation and behavior prior to screening) between treatment groups within region, and the difference in the distribution of effect modifier (baseline subcutaneous sumatriptan use). Given the small sample size in North America, the interaction of region by treatment could also be a spurious finding.

The patient populations in the chronic and episodic studies had a similar mean age, and were predominantly male, Caucasian, and from Europe. The numbers of weekly attacks at baseline were similar (17.5 ± 10.0 episodic (20); 18.8 ± 10.2 chronic). One between-study difference was that preventive medications were allowed in the cCH trial, but not in the eCH trial. In the eCH trial, 63% of patients used at least one preventive medication, with 49.8% of all patients using verapamil; however, a subgroup analysis by baseline

### Table 3. Summary of adverse events during the double-blind treatment period.a

| Category                                      | Placebo (N = 120) | GMB 300 mg (N = 117) |
|-----------------------------------------------|-------------------|----------------------|
| Deaths, n (%)                                 | 0                 | 0                    |
| Serious adverse events, n (%)                 | 3 (2.5)           | 2 (1.7)              |
| Atrial fibrillation                           | 0                 | 1 (0.9)              |
| Constipation                                  | 0                 | 1 (0.9)              |
| Melena                                        | 1 (0.8)           | 0                    |
| Non-cardiac chest pain                        | 1 (0.8)           | 0                    |
| Depression                                    | 1 (0.8)           | 0                    |
| Discontinuation due to adverse events, n (%)  | 1 (0.8)           | 1 (0.9)              |
| Atrial fibrillation                           | 0                 | 1 (0.9)              |
| Palpitations                                  | 1 (0.8)           | 0                    |
| Patients with ≥ 1 treatment-emergent adverse event, n (%)b | 75 (62.5) | 84 (71.8) |
| Injection site pain                           | 11 (9.2)          | 13 (11.1)            |
| Nasopharyngitis                                | 15 (12.5)         | 12 (10.3)            |
| Injection site erythema                       | 1 (0.8)           | 8 (6.8)c             |
| Nausea                                        | 6 (5.0)           | 6 (5.1)              |
| Back pain                                     | 1 (0.8)           | 5 (4.3)              |
| Dizziness                                     | 5 (4.2)           | 5 (4.3)              |
| Fatigue                                       | 7 (5.8)           | 5 (4.3)              |
| Influenza-like illness                         | 1 (0.8)           | 5 (4.3)              |
| Injection site pruritus                        | 1 (0.8)           | 5 (4.3)              |
| Pain in extremity                              | 1 (0.8)           | 4 (3.4)              |
| Dysmenorrheaad                                | 0                 | 1 (3.2)              |
| Menstrual disorderad                           | 0                 | 1 (3.2)              |
| Gastroenteritis                                | 1 (0.8)           | 3 (2.6)              |
| Myalgia                                       | 3 (2.5)           | 3 (2.6)              |
| Pruritus                                       | 0                 | 3 (2.6)              |
| Pyrexia                                       | 1 (0.8)           | 3 (2.6)              |
| Tinnitus                                      | 1 (0.8)           | 3 (2.6)              |
| Vomiting                                      | 3 (2.5)           | 3 (2.6)              |

GMB: galcanezumab; N: number of patients in the population; n: number of participants within each specific category.

*aAdverse events were coded using terms from Medical Dictionary for Regulatory Activities version 20.1.

*bTreatment-emergent adverse events occurring with a frequency of ≥ 2% (before rounding) in the galcanezumab group are shown.

*p = 0.018.

*dDenominator adjusted for female-specific event.
verapamil or preventive drug use did not show a treatment interaction.

Other studies have also shown differential treatment effects between chronic and episodic CH. For instance, lithium demonstrated efficacy in a comparator trial in cCH, but not in a placebo-controlled trial in eCH (34,35). In the ACT-1 and -2 randomized, double-blind clinical trials, non-invasive vagus nerve stimulation versus sham for the acute treatment of CH showed efficacy in patients with eCH, but not in patients with cCH (36,37). Potential differences between eCH and cCH are supported by research suggesting the brain anatomy (38) and the chronobiology of patients with cCH differ from those of patients with eCH and healthy controls (39).

It is conceivable that differences exist between episodic and chronic CH related to the role (or degree of influence) of CGRP. Studies to date that have reported CGRP elevations during CH attacks that normalized after successful treatment of the attack with subcutaneous sumatriptan or oxygen were in patients with eCH (13,14). However, in a recent study, CGRP infusion provoked an attack in 50% of patients with cCH compared to 89% of patients with eCH during an active cluster period (15), suggesting possible pathophysiological differences between the chronic and episodic subtypes and a different role of CGRP in cCH than in eCH.

It is also possible that cCH is more treatment-resistant than eCH. Based on reported clinical observations, a subset of patients with cCH who do not respond adequately to existing treatment options may be refractory to preventive treatments (36,40). These observations have resulted in a recommendation to establish diagnostic criteria for refractory cCH (40). In this study, patients who had inadequate responses to prior and current preventive treatments were not excluded, and 63% were on preventive treatments at baseline, suggesting an inadequate response to those preventives. Additionally, the percentage of patients reporting lifetime suicidal ideation and behavior at baseline was higher in the cCH study compared to the eCH study (ideation: 23% vs. 13%; behavior: 4% vs. 1%, respectively), also suggesting a more severely affected patient population. However, as approximately 30% of patients in the eCH study were not in an active cluster period at the time of the baseline assessment of lifetime suicidality, this may have contributed to the lower reported frequency in the eCH study compared to the cCH study.

Galcanezumab-treated patients had a high completion rate (96.6%) and low rate of discontinuation due to AEs (<1%). There was a higher frequency of treatment-emergent AEs in the galcanezumab group compared with the placebo group, which was due primarily to injection site-related treatment-emergent AEs. Overall, the safety of galcanezumab in patients with cCH was consistent with that seen in patients in the eCH and episodic and chronic migraine trials (17–20).

This study does have limitations. The patient population was predominantly European, which may limit generalizability of these results to patients in other geographies. Restrictions in the inclusion criteria of this study may also limit the generalizability of the results. The number of failed preventive drugs prior to study entry was not collected, and this information may have contributed to an understanding of the extent to which patients were treatment resistant. It is possible that patients with cCH may take longer to respond adequately to preventive CGRP antibody therapy, though conducting a longer placebo-controlled study in such a severely affected patient population would be challenging. This study includes a 52-week open-label extension; however, the results are not yet available.

### Table 4. Summary of least squares mean changes from baseline to endpoint in blood pressure, pulse, and weight.

|                          | Placebo N = 119 | Galcanezumab N = 117 | Least squares mean differenceb |
|--------------------------|-----------------|-----------------------|-------------------------------|
| Systolic blood pressure, |                 |                       |                               |
| Least squares mean change from baseline, mm Hg⁷ | −1.33 | 0.11 | 1.44 |
| Diastolic blood pressure, |                 |                       |                               |
| Least squares mean change from baseline, mmHg⁷ | −1.74 | 0.18 | 1.92⁸ |
| Pulse, least squares mean change from baseline, beats/minute⁷ | −0.85 | 0.60 | 1.45 |
| Weight, least squares mean change from baseline, kg⁷ | 0.26 | −0.00 | −0.26 |

*From baseline to the final post-baseline value during the double-blind treatment period.

*Least squares mean treatment differences are derived relative to placebo using analysis of covariance model: Change from baseline = treatment, pooled investigative site, and baseline value.

⁸p = 0.044 for between treatment comparison for change from baseline.
Conclusion
The primary and key secondary endpoints were not met in this cCH prevention trial. The safety of galcanezumab in patients with cCH was consistent with that of patients with eCH and migraine.

Clinical implications
- The disease burden of chronic cluster headache is substantial and there is a significant unmet need for new treatment.
- Treatment with galcanezumab 300 mg did not achieve its primary endpoint (overall mean change from baseline in weekly attack frequency across weeks 1–12) in patients with chronic cluster headache.
- Galcanezumab safety was consistent with that of patients with episodic cluster headache and migraine.

Acknowledgements
Most importantly, the authors thank the patients who participated in the study, their families, and the following investigators and study personnel: Jean Schoenen, Centre Hospitalier Regional de la Citadelle; Koen Paemelere, Universitair Ziekenhuis Gent; Marek Gawel, Stroyan Research; Suzanne Christie, Ottawa Headache Centre Research Inc.; Guy Boudreau, Centre de Traitement Neurologique; Rigmor Højland Jensen, Glostrup Hospital; Markus Färkkilä, Helsingin Päiänsärkykeskus; Markku Niissila, Terveystalo Pulsi; Matti Ilmavirta, Suomen Terveystalo; Caroline Roos, Hospital Lariboisière; Michel Lanteri-Minet, Hôpital de Cimiez; Christian Lucas, CHRU de Lille Hôpital Roger Salengro; Anne Donnet, APHM Hôpital de la Timone; Christelle Creach, CHU St Etienne Hospital Nord; Dagny Holle-Lee, Universitätsklinikum Essen; Arne May, Universitätsklinikum Hamburg – Eppendorf; Andreas Straube, Klinikum der Universität München; Charly Gaul, Migräne- und Kopfschmerzklinik GmbH & Co. KG; Philipp Stude, Praxis Dr. Philipp Stude; Peter Storch, Universitätsklinikum Jena; Nikolaos Fakas, 401 Army General Hospital of Athens; Dimos-Dimitrios Mitiskostas, Eginition Hospital of Athens; Massimo Leone, Istituto Neurologico Carlo Besta; Pierangelo Geppetti, Azienda Ospedaliera Universitaria Careggi; Cristina Tassorelli, Fondazione Istituto Neurologico Nazionale C. Mondino; Emile Couturier, Boerhaave Medisch Centrum; Wim Mulleners, Canisius-Wilhelmina Ziekenhuis; Jose Miguel Lainez Andres, Hospital Clínico Universitario de Valencia; Patricia Pozo-Rosich, Headache Unit, Neurology Department, Hospital Universitari Vall d’Hebron, Headache Research Group, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona; Peter Goadsby, King’s College Hospital; Nicholas Silver, Walton Centre for Neurology and Neurosurgery; Fayyaz Ahmed, Hull Royal Infirmary; Brendan Davies, Royal Stoke University Hospital; Cori Millen, Summit Headache and Neurologic Institute; Ana Recoder-Montilla, Children’s Hospital of Philadelphia; Stephen Silberstein, Thomas Jefferson University; Teshamae Monteith, University of Miami; Herbert Markley, New England Regional Headache Center, Inc.; Joel Saper, Michigan Head, Pain and Neurological Institute; David Kudrow, California Medical Clinic for Headache; Nada Hindiyeh, Stanford University Hospital; David Watson, West Virginia University Hospital; Kavita Kalidas, Tampa General Hospital; Rashmi Halker Singh, Mayo Clinic of Scottsdale; Deborah Friedman, Southwestern Medical Center Dallas; Peter McAllister, New England Institute for Clinical Research; Christopher Gottschalk, Yale University School of Medicine; Arifulla Khan, Northwest Clinical Research Center. Lori Kornberg, PhD, (Syneos Health, Raleigh, NC) provided writing assistance.

Declaration of conflicting interests
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DWD reports the following conflicts: Personal fees: Amgen, AEON, Association of Translational Medicine, University Health Network, Daniel Edelman Inc., Autonomic Technologies, Axsome, Aural Analytics, Allergan, Alder BioPharmaceuticals, Biohaven, Charlestown Laboratories, Clexio, Dr Reddy’s Laboratories/Promius, Electrocore LLC, Eli Lilly, eNeura, NeuroLife, Novartis, Ipsen, Impel, Satsuma, Supernus, Sun Pharma (India), Theranica, Teva, Vedanta, WL Gore, Nocira, PSL Group Services, University of British Columbia, XoC, Zosano, ZP Opcs, Foresite Capital, Oppenheimer; Upjohn (Division of Pfizer), Pieris, Revance, Equinox, Salvia, Amak Health. CME fees or royalty payments: HealthLogic, Medcom Worldwide, MedLogix Communications, Mednet, Miller Medical, PeerView, WebMD Health/Medscape, Chameleon, Academy for Continued Healthcare Learning, Universal Meeting Management, Haymarket, Global Scientific Communications, Global Life Sciences, Global Access Meetings, UpToDate (Elsevier), Oxford University Press, Cambridge University Press, Wolters Kluwer Health; Stock options: Precon Health, Aural Analytics, Healint, Theranica, Second Opinion/Mobile Health, Epifen, GBS/Nocira, Matterhorn/Ontologies, King-Devick Technologies; Consulting without fee: Aural Analytics, Healint, Second Opinion/Mobile Health, Epifen; Board of Directors: Epifen, Matterhorn/Ontologies, King-Devick Technologies; Patent: 17189376.1-1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis without fee; Research funding: American Migraine Foundation, US Department of Defense, PCORI, Henry Jackson Foundation; Professional society fees or reimbursement for travel: American Academy of Neurology, American Brain...
Foundation, American Headache Society, American Migraine Foundation, International Headache Society, Canadian Headache Society.

PJG reports grants and personal fees from Amgen and Eli-Lilly and Company, and personal fees from Alder Biopharmaceuticals, Allergan, Autonomic Technologies Inc., Biohaven Pharmaceuticals Inc., Electrocore LLC, eNeura, Impel Neuropharma, MundiPharma, Novartis, Teva Pharmaceuticals, Trigemina Inc., WL Gore, and personal fees from MedicoLegal work, Massachusetts Medical Society, Up-to-Date, Oxford University Press, and Wolters Kluwer; and a patent magnetic stimulation for headache assigned to eNeura without fee.

CL reports consulting fee/honoraria for advisory board membership or speaking from Novartis, TEVA, Sanofi, Grunenthal, Eli Lilly and Company, Biogen, and Ethypharm. He served as an investigator on clinical trials for Novartis and Eli Lilly and Company.

RJ reports speaker’s fees from Novartis, ATI, and Allergan and institutional payments for clinical trials with Eli Lilly and Company and ATI.

JB, JM, CZ, SKA, JYY, RC, and TO are employees and minor stock holders of Eli Lilly and Company.

Ethical approval and conduct
The study protocol was reviewed and approved by the appropriate institutional or ethical review board for each site. The study was conducted according to Good Clinical Practice and the Declaration of Helsinki guidelines. Patients provided written informed consent before undergoing study procedures.

Data sharing
Lilly provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available on request 6 months after the indication studied has been approved in the US and EU and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Eli Lilly and Company and/or one of its subsidiaries.

ORCID iD
Peter J Goadsby https://orcid.org/0000-0003-3260-5904

References
1. Hoffmann J and May A. Diagnosis, pathophysiology, and management of cluster headache. Lancet Neurol 2018; 17: 75–83.
2. Neschitt AD and Goadsby PJ. Cluster headache. BMJ 2012; 344: e2407.
3. Van Vliet JA, Eekers PJ, Haan J, et al. Features involved in the diagnostic delay of cluster headache. J Neurol Neurosurg Psychiatry 2003; 74: 1123–1125.
4. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38: 1–211.
5. Jensen RM, Lyngberg A and Jensen RH. Burden of cluster headache. Cephalalgia 2007; 27: 535–541.
6. Robbins MS, Starling AJ, Pringsheim TM, et al. Treatment of cluster headache: The American Headache Society evidence-based guidelines. Headache 2016; 56: 1093–1106.
7. May A, Leone M, Afra J, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Europ J Neurol 2006; 13: 1066–1077.
8. Ho TW, Edvinsson L and Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010; 6: 573–582.
9. Eftekhari S, Salvatore CA, Calamari A, et al. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 2010; 169: 683–696.
10. Rice FL, Xie JY, Albrecht PJ, et al. Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine. Cephalalgia 2017; 37: 1350–1372.
11. Goadsby PJ and Edvinsson L. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48–56.
12. Goadsby PJ, Edvinsson L and Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183–187.
13. Fanciullacci M, Alessandri M, Figini M, et al. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 1995; 60: 119–123.
14. Goadsby PJ and Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 1994; 117: 427–434.
15. Vollesen ALH, Snoer A, Beske RP, et al. Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: A randomized clinical trial. JAMA Neurol 2018; 75: 1187–1197.
16. Benschop RJ, Collins EC, Darling RJ, et al. Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthritis Cartilage 2014; 22: 578–585.
17. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic
migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. *Cephalalgia* 2018; 39: 1442–1454.

18. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial. *JAMA Neurol* 2018; 75: 1080–1088.

19. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. *Neurology* 2018; 91: e2211–e2221.

20. Goadsby PJ, Dodick DW, Leone M, et al. Trial of galcanezumab in prevention of episodic cluster headache. *N Engl J Med* 2019; 381: 132–141.

21. Dodick DW, Goadsby PJ, Lucas C, et al. Phase 3 randomized trial of galcanezumab in chronic cluster headache: Double-blind treatment. 19th Congress of the International Headache Society. *Cephalalgia* 2019; 39: 46–47.

22. Oakes TM, Dodick DW, Goadsby PJ, et al. Phase 3 placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment. 61st Annual Scientific Meeting American Headache Society. *Headache* 2019; 59: 19–20.

23. Pocock S and Simon R. Sequential treatment assignment with balancing for prognostic factors in controlled clinical trials. *Biometrics* 1975; 31: 103–115.

24. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). *Cephalalgia* 2013; 33: 629–808.

25. Lipton RB, Micieli G, Russell D, et al. Guidelines for controlled trials of drugs in cluster headache. *Cephalalgia* 1995; 15: 452–462.

26. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. *Am J Psychiatry* 2011; 168: 1266–1277.

27. Bourdage JS, Cook CA, Farrington DL, et al. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. *J Immunol Methods* 2007; 327: 10–17.

28. Butterfield AM, Chain JS, Ackermann BL, et al. Comparison of assay formats for drug-tolerant immunogenicity testing. *Bioanalysis* 2010; 2: 1961–1969.

29. US Department of Health and Human Services, Food and Drug Administration. Assay development and validation for immunogenicity testing of therapeutic protein products. Guidance for industry. Draft guidance. Pharmaceutical quality/CMC. Revision 1, https://www.fda.gov/media/77796/download (2016, accessed 4 June 2019).

30. US Department of Health and Human Services, Food and Drug Administration. Immunogenicity testing of therapeutic protein products – developing and validating assays for anti-drug antibody detection. Guidance for industry. Pharmaceutical quality/CMC, https://www.fda.gov/media/119788/download (2019, accessed 4 June 2019).

31. Koch GG, Tangen CM, Jung JW, et al. Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. *Stat Med* 1998; 17: 1863–1892.

32. Cui L, Hung HM and Wang SJ. Modification of sample size in group sequential clinical trials. *Biometrics* 1999; 55: 853–857.

33. The Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. *N Engl J Med* 1991; 325: 322–326.

34. Steiner TJ, Hering R, Couturier EG, et al. Double-blind placebo-controlled trial of lithium in episodic cluster headache. *Cephalalgia* 1997; 17: 673–675.

35. Goadsby PJ, de Coo IF, Silver N, et al. Non-invasive vagus nerve stimulation for the Acute Treatment of Episodic and Chronic Cluster Headache: A randomized, double-blind, sham-controlled ACT2 study. *Cephalalgia* 2018; 38: 959–969.

36. Silberstein SD, Mechtler LL, Kudrow DB, et al. Non-invasive vagus nerve stimulation for the Acute Treatment of Cluster Headache: Findings from the randomized, double-blind, sham-controlled ACT1 study. *Cephalalgia* 2018; 38: 959–969.

37. Barloese M, Haddock B, Lund NT, et al. Chronorisk in cluster headache: A tool for individualised therapy?. *Cephalalgia* 2018; 38: 2058–2067.

38. Mitsikostas DD, Edvinsson L, Jensen RH, et al. Refractory chronic cluster headache: A consensus statement on clinical definition from the European Headache Federation. *J Headache Pain* 2014; 15: 79.